Paper40144648
Antioxidants for the management of oral leukoplakia: A systematic review of randomized controlled trials.
Gopinath D and 3 others. J Oral Biol Craniofac Res, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Antioxidants for the management of oral leukoplakia: A systematic review of randomized controlled trials. Papers, record 40144648. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40144648
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antioxidants for the management of oral leukoplakia: A systematic review of randomized controlled trials.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23970935 | Multiple molecular and cellular mechanisms of action of lycopene in cancer inhibition. | Evid Based Complement Alternat Med | 2013 | https://conductscience.org/library/papers/23970935 | PubMed |
| 2 | 30443884 | Malignant transformation of oral leukoplakia treated with carbon dioxide laser: a meta-analysis. | Lasers Med Sci | 2019 | https://conductscience.org/library/papers/30443884 | PubMed |
| 3 | 36656190 | A comparative investigation of the activity of superoxide dismutase in patients with leukoplakia and healthy controls. | Indian J Dent Res | 2022 | https://conductscience.org/library/papers/36656190 | PubMed |
| 4 | 29952268 | A Review on Free Radicals and Antioxidants. | Infect Disord Drug Targets | 2020 | https://conductscience.org/library/papers/29952268 | PubMed |
| 5 | 21299897 | Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. | Mol Cancer | 2011 | https://conductscience.org/library/papers/21299897 | PubMed |
| 6 | 37760056 | Antioxidant Use after Diagnosis of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review of Application during Radiotherapy and in Second Primary Cancer Prevention. | Antioxidants (Basel) | 2023 | https://conductscience.org/library/papers/37760056 | PubMed |
| 7 | 28929051 | Comparison of effectiveness of Calendula officinalis extract gel with lycopene gel for treatment of tobacco-induced homogeneous leukoplakia: A randomized clinical trial. | Int J Pharm Investig | 2017 | https://conductscience.org/library/papers/28929051 | PubMed |
| 8 | 31462531 | RoB 2: a revised tool for assessing risk of bias in randomised trials. | BMJ | 2019 | https://conductscience.org/library/papers/31462531 | PubMed |
| 9 | 38938085 | Surgical treatment compared with "wait and see" in patients affected by oral leukoplakia to prevent oral cancer: Preliminary data from a multicenter randomized controlled trial. | Oral Dis | 2025 | https://conductscience.org/library/papers/38938085 | PubMed |
| 10 | 24932187 | Oxidant-antioxidant status in tissue samples of oral leukoplakia. | Dent Res J (Isfahan) | 2014 | https://conductscience.org/library/papers/24932187 | PubMed |
| 11 | 38155549 | Antioxidant treatments in patients with oral submucous fibrosis: A systematic review. | J Oral Pathol Med | 2024 | https://conductscience.org/library/papers/38155549 | PubMed |
| 12 | 31981993 | Oral potentially malignant disorders: A comprehensive review on clinical aspects and management. | Oral Oncol | 2020 | https://conductscience.org/library/papers/31981993 | PubMed |
| 13 | 15116757 | Biological properties of curcumin-cellular and molecular mechanisms of action. | Crit Rev Food Sci Nutr | 2004 | https://conductscience.org/library/papers/15116757 | PubMed |
| 14 | 37971722 | Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. | JAMA Oncol | 2024 | https://conductscience.org/library/papers/37971722 | PubMed |
| 15 | 27656569 | Prevalence of Carcinomatous Foci in Oral Leukoplakia: A Clinicopathologic Study of 546 Indian Samples. | J Clin Diagn Res | 2016 | https://conductscience.org/library/papers/27656569 | PubMed |
| 16 | 25156040 | Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: a randomized controlled trial. | Int J Cancer | 2015 | https://conductscience.org/library/papers/25156040 | PubMed |
| 17 | 27865803 | Leukoplakia-A Diagnostic and Management Algorithm. | J Oral Maxillofac Surg | 2017 | https://conductscience.org/library/papers/27865803 | PubMed |
| 18 | 38654673 | Oral leukoplakia treated with laser and scalpel: Interim trial results of recurrence and malignancy. | Oral Dis | 2024 | https://conductscience.org/library/papers/38654673 | PubMed |
| 19 | 38817004 | Clinical aspects of oral cancer and potentially malignant disorders in South and Southeast Asia. | Oral Dis | 2025 | https://conductscience.org/library/papers/38817004 | PubMed |
| 20 | 27267893 | A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia. | Cancer Prev Res (Phila) | 2016 | https://conductscience.org/library/papers/27267893 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40144648
GET https://conductscience.org/api/papers/v1/40144648/references?page=2